COMMUNIQUÉS West-GlobeNewswire

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22/09/2025
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1 -mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The [...]
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
22/09/2025
Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT (ISIN: [...]
CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE®
22/09/2025
Communiqué de presse CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le développement et l'autorisation par la FDA de ZEPIZURE® DIJON, France – 22 septembre 2025 (07H30 CET) – CROSSJECT (ISIN [...]
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre
22/09/2025
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre NANTES, France – 22 septembre 2025, 8 h 00 – OSE [...]
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
22/09/2025
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30 th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics [...]
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
22/09/2025
Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role [...]
C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme
22/09/2025
C4X Discovery Holdings Ltd C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to support once-daily [...]
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
22/09/2025
MILAN, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised [...]
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
22/09/2025
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial ZUG, Switzerland, Sept. 22, 2025 ( [...]
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
22/09/2025
ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled [...]
Yangtze River Pharmaceutical Group’s Innovative Anti-insomnia Drug Fazamorexant Debut at the World Sleep Congress 2025
22/09/2025
TAIZHOU, Jiangsu, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug independently developed by Yangtze River [...]
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
22/09/2025
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over [...]
Communiqué de presse : Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP
22/09/2025
Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP Recommandation pour les adultes et les adolescents, sur la [...]
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22/09/2025
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced [...]
Communiqué de presse : Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente
22/09/2025
Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Paris, le 22 septembre 2025 . La Food and Drug Administration (FDA [...]
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
22/09/2025
IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacy Data showed [...]
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
21/09/2025
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was [...]
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
21/09/2025
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported high satisfaction [...]
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
20/09/2025
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple [...]

Pages